title: 300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis.
abstract: The once-daily 300 index of reactivity (IR) house dust mite (HDM) tablet (Actair®; Stallergenes Greer, Antony, France/Shionogi & Co. Ltd., Osaka, Japan) is the first sublingual immunotherapy (SLIT) tablet to be approved for the treatment of HDM-induced allergic rhinitis. Areas covered: This drug profile reviews the current body of evidence on the efficacy, safety and tolerability of the 300 IR HDM tablet, its pharmacodynamics, and its role in clinical practice. Expert commentary: Data from its clinical development program demonstrate favorable efficacy and safety in adults and adolescents with HDM-induced allergic rhinitis, irrespective of mono- or polysensitization status, or the presence of comorbid mild asthma. The 300 IR HDM tablet is effective from as early as 2 months after treatment initiation, providing allergic symptom control and a reduction in the need for symptomatic medication, while improving health-related quality of life. Clinical efficacy is maintained for 1 year after treatment is stopped.
authors.affiliation: a Department of Pulmonology - Division of Allergy , Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier and Sorbonne Universités , UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, Paris , France.
authors.forename: Pascal
authors.initials: P
authors.lastname: Demoly
authors.affiliation: b Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine , Chiba University , Chiba , Japan.
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Okamoto
authors.affiliation: c Ottawa Allergy Research Corporation , University of Ottawa Medical School , Ottawa , Canada.
authors.forename: William H
authors.initials: WH
authors.lastname: Yang
authors.affiliation: d UPRES EA 220, Université de Versailles Saint-Quentin , Department of Airway Diseases, Foch Hospital , Suresnes , France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Devillier
authors.affiliation: e Allergy-Centre Charité , Charité-Universitätsmedizin Berlin , Berlin , Germany.
authors.forename: Karl-Christian
authors.initials: KC
authors.lastname: Bergmann
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D039741:Antigens, Dermatophagoides / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D039981:Pyroglyphidae / Q000276:immunology; D011788:Quality of Life; D065631:Rhinitis, Allergic / Q000276:immunology / Q000628:therapy*; D063729:Sublingual Immunotherapy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D039741:Antigens, Dermatophagoides
keywords: Allergy immunotherapy; allergic rhinitis; clinical trial; efficacy; house dust mite allergy; safety; sublingual immunotherapy